NCT03216213 is a NA clinical trial of Frame in Control, sponsored by Yale-NUS College.

Who is sponsoring NCT03216213?

NCT03216213 is sponsored by Yale-NUS College.

What drugs are being tested in NCT03216213?

Interventions in NCT03216213: Frame, Norms.

What condition does NCT03216213 study?

NCT03216213 studies Control, Behavior.

Is NCT03216213 still recruiting?

NCT03216213 is currently completed. Last updated 8 March 2019.

Last reviewed 2019-03-08 · How we verify

NCT03216213

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Attitudes Towards Organ Donation in Singapore

Completed NA Last updated 8 March 2019

What this trial tests

NA trial testing Frame in Control in 180 participants. Completed in 8 February 2019.

Timeline

27 September 2018

Primary endpoint
8 February 2019

8 February 2019

Quick facts

Lead sponsor	Yale-NUS College
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	180
Start date	27 September 2018
Primary completion	8 February 2019
Estimated completion	8 February 2019
Sites	1 location across Singapore

Drugs / interventions tested

Frame
Norms

Conditions studied

Control — all drugs for Control →
Behavior — all drugs for Behavior →

Sponsor

Yale-NUS College

Who can join

21 and older, any sex, with Control or Behavior. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

One survey is conducted. Exploring the effect of different messages on family members' decision making on organ donation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Control

Currently open trials in the same condition.

NCT06750107 — Testing the Efficacy of Safe South Africa · Phase 3 · active not recruiting
NCT06116292 — Impact of the Implementation of a Telemedicine Program on Patients Diagnosed with Asthma · NA · recruiting
NCT06169540 — Salivary Extracellular Vesicle Associated lncRNAs in Heart Failure (SEAL-HF) · recruiting
NCT05517811 — Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection · recruiting

Other Yale-NUS College trials

Trials by the same sponsor.

NCT06440785 — Taylor Swift and Mental Health Outcomes · recruiting
NCT06440798 — Mental Health Content and Mental Health Outcomes · recruiting
NCT04967846 — Social Media Effects on Mental Health · completed
NCT04918849 — WhatsApp in India During the COVID-19 Pandemic · unknown
NCT04448704 — Understanding the Mental Health of Migrant Workers During the COVID-19 Outbreak · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03216213 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale-NUS College
Last refreshed: 8 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03216213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing